Melanoma | Clinical

Darovasertib/Crizotinib Demonstrates Efficacy in Metastatic Uveal Melanoma

September 13, 2022

With an overall response rate of 50% and greater than 5 months median progression-free survival in patients with first-line metastatic uveal melanoma, darovasertib and crizotinib shows a compelling clinical efficacy profile.